Haematologica

Published by: Ferrata Storti Foundation  

People

  1. Levine
    Levine
  2. Mauro
    Mauro
  3. Zelenetz
    Zelenetz
  4. Abdel-Wahab
    Abdel-Wahab
  5. Stein
    Stein
  6. Rampal
    Rampal
  7. Sadelain
    Sadelain
  8. Devlin
    Devlin
  9. Giralt
    Giralt
  10. Horwitz
    Horwitz

Groups

  1. Department of Medicine (267)
  2. Hematologic Malignancies, Division of (265)
  3. Center for Hematologic Malignancies (246)
  4. Adult Leukemia (99)
  5. GSK Faculty (64)
  6. Lymphoma (59)
  7. Executive Committee, Center for Hematologic Malignancies (58)
  8. Hematologic Malignancies Research (42)
  9. Myeloma (38)
  10. Human Oncology and Pathogenesis Program (36)
Search Within
Formats
  1. Meeting Abstract (178)
  2. Journal Article (102)
  3. Research Letter (16)
  4. Editorial (11)
  5. Review (7)
  6. Correspondence (1)
  7. Guidelines (1)
Groups
  1. Department of Medicine (267)
  2. Hematologic Malignancies, Division of (265)
  3. Center for Hematologic Malignancies (246)
  4. Adult Leukemia (99)
  5. GSK Faculty (64)
  6. Lymphoma (59)

More Groups

People
  1. Carl Landgren (25)
  2. Ross Levine (24)
  3. Martin Tallman (23)
  4. Andrew Zelenetz (21)
  5. Michael Mauro (21)
  6. Anas Younes (15)

More People

Years
  1. 2024 (3)
  2. 2023 (17)
  3. 2022 (20)
  4. 2021 (13)
  5. 2020 (18)
  6. 2019 (11)

More Years

Publishers
  1. Ferrata Storti Foundation (316)

Results (316)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Multivariate analysis of PFS from the AETHERA trial: A phase 3 study of brentuximab vedotin consolidation after autologous stem cell transplant for HL
    Meeting Abstract

    Walewski, J.; Nademanee, A.; Masszi, T.; Holowiecki, J.; Abidi, M.; Chen, A.; Stiff, P.; Viviani, S.; Bachanova, V.; Sweetenham, J.; more...
    Haematologica (2015)

    Fulltext@MSK | Save
  • Ibrutinib in previously treated patients with Waldenström's macroglobulinemia is highly active, produces durable responses, and is impacted by MYD88 and CXCR4 mutation status
    Meeting Abstract

    Treon, S.; Tripsas, C.; Meid, K.; Warren, D.; Varma, G.; Green, R.; Argyropoulos, K.; Yang, G.; Cao, Y.; Xu, L.; more...
    Haematologica (2015)

    Fulltext@MSK | Save
  • Heavy light chain ratio normalization allows identification of electrophoretic non-complete response patients with improved outcomes: A long term follow up update for BMT CTN 0102 correlative study
    Meeting Abstract

    D'Souza, A.; Pasquini, M.; Logan, B.; Giralt, S.; Krishnan, A.; Antin, J.; Howard, A.; Horowitz, M.; Goodman, S.; Laport, G.; more...
    Haematologica (2015)

    Fulltext@MSK | Save
  • A prior cancer diagnosis is not a risk factor for the developement of subsequent cancers in multiple myeloma patients
    Meeting Abstract

    Jonsdottir, G.; Lund, S. H.; Bjorkholm, M.; Hultcrantz, M.; Landgren, O.; Kristinsson, S. Y.
    Haematologica (2015)

    Fulltext@MSK | Save
  • Cardiovascular (CV) and pulmonary adverse events (AES) in patients (PTS) treated with BCR-ABL tyrosine kinase inhibitors (TKIS): Updated analysis from the FDA Adverse Event Reporting System (FAERS)
    Meeting Abstract

    Cortes, J.; Mauro, M.; Steegmann, J. L.; Saglio, G.; Soitkar, A.; Wallis, N.
    Haematologica (2015)

    Fulltext@MSK | Save
  • Safety of idelalisib in B-cell malignancies: Integrated analysis of eight clinical trials
    Meeting Abstract

    Coutre, S.; Barrientos, J.; Brown, J.; de Vos, S.; Furman, R.; Keating, M.; O'Brien, S.; Pagel, J.; Sharman, J.; Zelenetz, A.; more...
    Haematologica (2015)

    Fulltext@MSK | Save
  • Ag-221, an oral, selective, first-in-class, potent inhibitor of the IDH2 mutant enzyme, induced durable responses in a phase 1 study of IDH2 mutation-positive advanced hematologic malignancies
    Meeting Abstract

    DiNardo, C.; Stein, E. M.; Altman, J. K.; Collins, R.; DeAngelo, D. J.; Fathi, A. T.; Flinn, I.; Frankel, A.; Levine, R. L.; Medeiros, B. C.; more...
    Haematologica (2015)

    Fulltext@MSK | Save
  • Clinical safety and activity of AG-120, a first-in-class, potent inhibitor of the IDH1 mutant protein, in a phase 1 study of patients with advanced IDH1-mutant hematologic malignancies
    Meeting Abstract

    de Botton, S.; Pollyea, D. A.; Stein, E. M.; DiNardo, C.; Fathi, A. T.; Roboz, G. J.; Collins, R.; Swords, R. T.; Flinn, I.; Altman, J. K.; more...
    Haematologica (2015)

    Fulltext@MSK | Save
  • DNMT3A R882 mutation promote chemoresistance and therapeutic relapse through impaired DNA-damage sensing
    Meeting Abstract

    Guryanova, O.; Shank, K.; Garrett-Bakelman, F.; Spitzer, B.; Ganzel, C.; Rapaport, F.; Keller, M.; Evangelista, L.; Glass, J.; Rowe, J.; more...
    Haematologica (2015)

    Fulltext@MSK | Save
  • BCl6 and EZH2 cooperate to assemble non-canonical PRC1-BCOR complex to mediate germinal center formation and promote lymphomagenesis by repressing bivalent chromatin domains
    Meeting Abstract

    Béguelin, W.; Teater, M.; Hatzi, K.; Jiang, Y.; Gascoyne, R. D.; Abdel-Wahab, O.; Shaknovich, R.; Bardwell, V. J.; Elemento, O.; Melnick, A. M.
    Haematologica (2015)

    Fulltext@MSK | Save

    • Haematologica – authorized name for:

    Name ISSN / ISBN Publisher
    Haematologica 0390-6078 Pensiero Scientifico Editor
    Haematologica 15928721 Unknown
    Haematologica 03906078 Ferrata Storti Foundation Published Under A Cc By Nc License
    Haematologica 03906078 Ferrata Storti Foundation
    Haematologica 0390-6078 Unknown
    Haematologica 15928721 Ferrata Storti Foundation
    Haematologica 0390-6078 Ferrata Storti Foundation
    Haematologica 03906078 Unknown
    Haematologica-The Hematology Journal 0390-6078 Unknown
    Haematologica. 15928721 Unknown